Small-Molecule Entry Inhibitors Block SARS-CoV-2 Spike Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral measures for SARS-COV-2, such as vaccines, are vulnerable to genetic drift and evolution, necessitating the development of cost-effective, scalable small-molecule entry inhibitors that can effectively block viral replication and transmission.
Innovation Solution
Development of small, low molecular weight compounds that bind to the interface of the SARS Spike protein receptor binding domain (RBD) and the host cell ACE-2 receptor, utilizing computer-aided drug design (CADD) to identify and optimize compounds like formula (IIa) and its derivatives, which inhibit the S-RBD and ACE-2 interaction, potentially used in combination with remdesivir for enhanced efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vaccines are used as antiviral measures, then immunity can be provided, but vulnerability to genetic drift and evolution occurs
Solution Approach 1:
The invention targets a specific functional segment of the viral life cycle (entry phase) rather than relying on broad immune responses. By segmenting the antiviral approach to focus specifically on blocking the S-RBD/ACE2 interaction, the compound maintains effectiveness against variants while reducing vulnerability to genetic drift in other viral regions.
Solution Approach 2:
The small molecule compound changes the physical-chemical parameters of the viral entry process by binding to the S-RBD/ACE2 interface. This parameter change (blocking the interaction) provides consistent inhibition across variants, overcoming the adaptability issue with vaccines that rely on recognizing specific viral epitopes that may mutate.
2Ease of manufacture
If small-molecule entry inhibitors are developed, then cost-effectiveness and scalability improve, but manufacturing complexity increases
Solution Approach 1:
The invention uses small molecule compounds that can be synthesized through established chemical manufacturing processes, replacing the need for complex biological manufacturing required for vaccines. This approach prioritizes cost-effectiveness and scalability, accepting that manufacturing processes will require optimization but benefiting from well-established chemical production infrastructure.
3Reliability
If compounds bind to S-RBD and ACE2 interface, then viral entry is blocked, but specificity and selectivity challenges arise
Solution Approach 1:
The small molecule compound acts as an intermediary that binds to the interface between S-RBD and ACE2, physically blocking their interaction without requiring the compound to bind tightly to either protein individually. This intermediary mechanism provides reliable viral entry inhibition while potentially reducing off-target effects compared to compounds that bind directly to essential host proteins.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds demonstrate sub-micromolar IC50 values, effectively inhibiting viral replication and showing synergistic effects with remdesivir, providing broad-spectrum activity against SARS-COV-2 and its variants, including South African, Scotland, and Delta variants, with a favorable pharmacokinetic profile.
Implementation Method 1
small, low molecular weight compounds that bind to the interface of the SARS Spike protein receptor binding domain (RBD) and the host cell ACE-2 receptor
Data Source
AI summary
The present invention relates to compounds, compositions, and methods, for treating viral infections. In particular, entry inhibitor compounds are disclosed for treatment of coronavirus infections, including SARS-COV-1 and SARS-COV-2 infections. The compounds bind to the interface of a SARS-COV-2 spike protein receptor binding domain (RBD) and a host cell ACE-2 receptor. The entry inhibitor compounds show antiviral activity, favorable kinetics, and temporally act at the entry of SARS-COV-2 infection. In embodiments, the compounds are used as medicaments for the inhibition of viral replication including SARS-COV-1 and/or SARS-COV-2 replication, for the treatment or prophylaxis of viral infections including SARS-COV-1 and SARS-COV-2 infections, and/or for the treatment or prophylaxis of an illness due to SARS-COV-1 and SARS-COV-2 infections.